-- Days : -- HRS : -- MIN : -- SEC

Register Now →

News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|June 19, 2024

Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates

Author(s)Derek van Amerongen, MD, MS, Soeren Mattke, MD, DSc, B. Joy Snider, MD, PhD

The panel discusses emerging therapies for Alzheimer disease that are currently in development, including donanemab, subcutaneous lecanemab, and ALZ-801.

Episodes in this series

A panel of 5 experts on Alzheimer disease

EP. 1 The Clinical and Economic Implications of Alzheimer Disease Across Patients, Families, and the Health Care System

B. Joy Snider, MD, PhD, and Maria Lopes, MD, MS

EP. 2 Recent Insights into the Pathophysiology of Alzheimer Disease

A panel of 5 experts on Alzheimer disease

EP. 3 Genetic Aspects of Alzheimer Disease

A panel of 5 experts on Alzheimer disease

EP. 4 The Patient Experience: From Symptoms to Diagnosis of Alzheimer Disease

Video 5 - "Potential Consequences of Early Diagnosis of Alzheimer Disease"

EP. 5 Potential Consequences of Early Diagnosis of Alzheimer Disease

Video 5 - "Potential Consequences of Early Diagnosis of Alzheimer Disease"

EP. 6 Criteria for Diagnosing Alzheimer Disease and the Role of Testing

A panel of experts on Alzheimer's disease

EP. 7 Exploring the Economic Impact of Advanced Approaches for Diagnosing Alzheimer Disease

A panel of experts on Alzheimer's disease

EP. 8 Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease

A panel of experts on Alzheimer's disease

EP. 9 Clinical Decision-Making for Alzheimer Disease Management

A panel of experts on Alzheimer's disease

EP. 10 Cost, Value, and Affordability of Treatment for Alzheimer Disease

A panel of 5 experts on Alzheimer disease

EP. 11 Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates

A panel of 5 experts on Alzheimer disease

EP. 12 Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden

A panel of 5 experts on Alzheimer disease

EP. 13 Payer Coverage Considerations for New Treatments for Alzheimer Disease

A panel of 5 experts on Alzheimer disease

EP. 14 Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook

Video content above is prompted by the following question(s):

Could you discuss disease modifying and other therapies for Alzheimer disease that are currently in development?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related to this article

In phase 3 PREVAIL, weekly gefurulimab cut MG-ADL scores by 4.2 points vs 2.6 with placebo at week 26 in adults with generalized myasthenia gravis | Image credit: Andrii - stock.adobe.com

October 30th, 2026

Weekly Gefurulimab Improves Daily Function in Generalized MG

Weekly gefurulimab cut MG-ADL scores by 4.2 points vs 2.6 with placebo at week 26 in adults with generalized myasthenia gravis in the PREVAIL study.

Trending on AJMC

First-Line Vitiligo Treatment: Topical JAK Inhibitors and Phototherapy

Unanswered Questions in First- and Second-Line mCRC Care

Planning for Third-Line Therapy and Treatment Rechallenge in mCRC

Multidisciplinary Care for Vitiligo: Beyond Dermatology

Precision Drugs Meet Payer Realities